Clemex concludes a strategic alliance with RAL Diagnostics
August 16 2011 - 10:35AM
PR Newswire (Canada)
MONTREAL, Aug. 16, 2011 /CNW/ -- The alliance based on a Share Swap
between the two Corporations licenses European market distribution
of the new Clemex system for Haematology applications Symbol:
CXG.A-TSX-V www.clemex.com Shares Outstanding: 20,749,810
MONTREAL, Aug. 16, 2011 /CNW Telbec/ - Clemex Technologies Inc.
(TSXV: CXG.A) announces it has concluded a strategic alliance with
its European partner RAL Diagnostics located in Martillac, France,
to notably support the marketing of its new instrument being
developed for the Haematology sector. According to the partnership
signed between the two Corporations, RAL will immediately become
the exclusive distributor of the new microscopy instruments
developed by Clemex for haematology and other life sciences
applications in Europe. Clemex, on the other hand, developed its
new instrument for haematology to primarily use the new MCDH stain
solution created by RAL and will also engage in working to develop
new microscopy instruments in the future using the various staining
solutions created and manufactured by RAL. A commercial partnership
in Europe Furthermore, RAL Diagnostic immediately becomes dealer of
other image analysis products manufactured by Clemex for all other
microscopy applications in France, Belgium and Switzerland.
Finally, RAL will become the privileged business partner of Clemex
products for all of Europe within a year, and will eventually
become in charge of all commercial activities such as distribution
and marketing for all of Europe. With such an important partner,
Clemex, which was only partially present in Europe, will strengthen
its presence and should increase its sales significantly to reach
North America sales levels in the near future. Business transaction
After completion of this transaction, which is subject to approval
by the regulated authorities, Clemex will hold 10% of RAL
Diagnostics share capital. They will obtain in return 3 250 000
voting shares which will be issued by Clemex, representing 13.5% of
all outstanding voting shares issued by the Company. RAL
Diagnostics, which already held 750 000 shares from a private
placement concluded in 2008, will then hold, 16.7% of the
outstanding voting shares of Clemex. At the time of signing this
historic and unprecedented agreement, the president and CEO of
Clemex Technologies declared:" We are very pleased to finally sign
this partnership, which brings a new momentum to the work
collaboration already set in place between the two Companies. We
have been working with RAL for a number of years and had began the
development of this new haematology instrument with some exchange
of trade secret information and technologies in anticipation of
this partnership. We had also been seeking different ways to
improve our presence in Europe on a permanent basis for years, and
this partnership is the perfect opportunity to realize this
objective, at very low cost for Clemex. RAL Diagnostics will
also increase its sales with the distribution of our products in
Europe. This partnership becomes a win-win situation for both
parties. Furthermore, the swap of shares between the two companies
demonstrates mutual commitment to develop the European market and
to work together towards developing various competitive and
distinct image analysis instruments." For its part, the president
and CEO of RAL Diagnostics, Frédéric Imbs added:" We are absolutely
delighted about signing this partnership which can only have
positive financial fallback for us on average term. We have
absolute trust in Clemex's expertise and in their ability to
develop innovative image analysis instruments. We are convinced
that this strategic alliance between the two companies will be
synergetic and a carrier for both parties. One must know and
understand that an image analysis system, even highly-performing,
cannot detect uncoloured blood smear slides, or any other tissue
slide. That's where the knowledge of RAL Diagnostics will
intervene, as we have developed world-class staining solutions for
these applications. Our products will allow Clemex's image analysis
systems to perform even better and therefore help in the most
complex and sophisticated needs of the market today, notably in the
haematology sector. There is no doubt that this partnership will be
profitable for both companies, and this, on both sides of the
Atlantic." About RAL Diagnostics RAL Diagnostics is a manufacturer
of biological stains intended for the field of human and animal
health, scientific research, medical diagnosis, and industry. These
stains are available in liquids or ready to use kits. RAL
Diagnostics serves 6,000 medical analysis laboratories and
anatomopathology laboratories of France thanks to a network of 35
distributors and 180 representatives. The company is present in
more than 40 countries in the world. About Clemex Technologies,
Inc. Clemex Technologies Inc. develops, manufactures and markets
image analysis systems and software used by quality control and
research microscopy laboratories. Clemex customer base spans
over many countries in America, Europe, Asia and encompasses major
Research and Development Centers, prestigious Universities and
large manufacturing industries in various fields including
healthcare, automotive, aerospace, raw materials manufacturing,
pharmaceuticals, mining and other sectors. The TSX Venture Exchange
has not reviewed and does not accept responsibility for the
adequacy and accuracy of this news release. To view this news
release in HTML formatting, please use the following URL:
http://www.cnw.ca/en/releases/archive/August2011/16/c4093.html p
bCLEMEX TECHNOLOGIES INC,/bb /bbr/ 800 Guimond,br/ Longueuil,
QC, Canada J4G 1T5, /p p Contact: /p p align="justify" Clément
Forgetbr/ Tel: 450.651.6573br/ Email: a
href="mailto:ir@clemex.com" cr="true"ir@clemex.com/a /p
Copyright
Clemex Technologies Inc. (TSXV:CXG.A)
Historical Stock Chart
From Jun 2024 to Jul 2024
Clemex Technologies Inc. (TSXV:CXG.A)
Historical Stock Chart
From Jul 2023 to Jul 2024